Surufatinib and Envafolimab as Second or More-line Therapy in Advanced Soft Tissue Sarcoma Patients
Status:
Not yet recruiting
Trial end date:
2027-02-02
Target enrollment:
Participant gender:
Summary
In this study, we investigated the efficacy and safty of surufatinib combined with
envafolimab followed by surufatinib as second or more - line therapy in advanced soft tissue
sarcoma patients. Patients who have failed at least the first-line therapy and have
progressive disease or cannot tolerate within 6 months before enrollment will be treated with
surufatinib combined with envafolimab.